Abstract
Brugada syndrome is a rare autosomal dominant condition characterized by mutations in cardiac sodium channels, which cause specific ECG findings and increase the risk of ventricular fibrillation and sudden cardiac death. Untreated Brugada syndrome has mortality of about 10% per year. The sole effective treatment is placement of an implantable cardiac defibrillator.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yap Y, et al. Drug-induced Brugada syndrome. Europace. 2009;11:989–94.
Di Diego J. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation. 2002;106(15):2004–11.
RodrÃguez-Mañero M, et al. The clinical significance of pregnancy in Brugada syndrome. Rev Esp Cardiol (Engl Ed). 2014;67(3):176–80.
Sorajja D, et al. Brugada syndrome and its relevance in the perioperative period. Ann Card Anaesth. 2015;18:403–13.
Mizusawa Y, Wilde A. Brugada Syndrome. Circ Arrhythm Electrophysiol. 2012;5:606–16.
BrugadaDrugs.org. [Online]. [cited 2016 June 14. Available from: http://www.brugadadrugs.org/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Mankowitz, S. (2018). Brugada Syndrome. In: Mankowitz, S. (eds) Consults in Obstetric Anesthesiology. Springer, Cham. https://doi.org/10.1007/978-3-319-59680-8_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-59680-8_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59679-2
Online ISBN: 978-3-319-59680-8
eBook Packages: MedicineMedicine (R0)